Literature DB >> 25708580

Penile cancer: Advanced penile cancer continues to elude systemic therapy.

Pranav Sharma1, Philippe E Spiess1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25708580     DOI： 10.1038/nrurol.2015.30

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Swedish National Penile Cancer Register: incidence, tumour characteristics, management and survival.

Authors:  Peter Kirrander; Amir Sherif; Bengt Friedrich; Mats Lambe; Ulf Håkansson
Journal:  BJU Int       Date:  2015-05-04       Impact factor: 5.588

2.  Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.

Authors:  Lance C Pagliaro; Dallas L Williams; Danai Daliani; Michael B Williams; William Osai; Michael Kincaid; Sijin Wen; Peter F Thall; Curtis A Pettaway
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

3.  Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis.

Authors:  Bradley C Carthon; Chaan S Ng; Curtis A Pettaway; Lance C Pagliaro
Journal:  BJU Int       Date:  2014-06       Impact factor: 5.588

4.  Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study.

Authors:  G P Haas; B A Blumenstein; R G Gagliano; C A Russell; S E Rivkin; D J Culkin; M Wolf; E D Crawford
Journal:  J Urol       Date:  1999-06       Impact factor: 7.450

5.  EAU guidelines on penile cancer: 2014 update.

Authors:  Oliver W Hakenberg; Eva M Compérat; Suks Minhas; Andrea Necchi; Chris Protzel; Nick Watkin
Journal:  Eur Urol       Date:  2014-11-01       Impact factor: 20.096

6.  Neoadjuvant chemotherapy in advanced penile carcinoma.

Authors:  Joost A P Leijte; J Martijn Kerst; Evert Bais; Ninja Antonini; Simon Horenblas
Journal:  Eur Urol       Date:  2007-02-14       Impact factor: 20.096

7.  Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma.

Authors:  Nadine Houédé; Laura Dupuy; Aude Fléchon; Philippe Beuzeboc; Gwenaëlle Gravis; Brigitte Laguerre; Christine Théodore; Stéphane Culine; Thomas Filleron; Christine Chevreau
Journal:  BJU Int       Date:  2015-04-27       Impact factor: 5.588

8.  A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).

Authors:  C Theodore; I Skoneczna; I Bodrogi; M Leahy; J M Kerst; L Collette; K Ven; S Marréaud; R D T Oliver
Journal:  Ann Oncol       Date:  2008-04-15       Impact factor: 32.976

9.  Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.

Authors:  Giuseppe Di Lorenzo; Carlo Buonerba; Piera Federico; Sisto Perdonà; Michele Aieta; Pasquale Rescigno; Carmine D'Aniello; Livio Puglia; Antonella Petremolo; Matteo Ferro; Alfredo Marinelli; Giovannella Palmieri; Guru Sonpavde; Vincenzo Mirone; Sabino De Placido
Journal:  BJU Int       Date:  2012-09-10       Impact factor: 5.588

10.  Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).

Authors:  S Nicholson; E Hall; S J Harland; J D Chester; L Pickering; J Barber; T Elliott; A Thomson; S Burnett; C Cruickshank; B Carrington; R Waters; A Bahl
Journal:  Br J Cancer       Date:  2013-10-29       Impact factor: 7.640
  10 in total
  1 in total

1.  Nomograms to predict overall and cancer-specific survival in patients with penile cancer.

Authors:  Wenbo Xu; Feng Qi; Yi Liu; Lizhuan Zheng; Zhengjun Kang
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.